Posted by Michael Wonder on 17 Aug 2021
Oncopeptides' Pepaxto receives a permanent J code, clarifying reimbursement processes in hospital outpatient and physician office settings of care
16 August 2021 - Oncopeptides today announced that the Centers for Medicare and Medicaid Services has established a specific billing Level II Healthcare Common Procedure Coding System code for Pepaxto.
J codes are product specific reimbursement codes assigned to outpatient and physician administered "buy and bill" products under Medicare Part B. Claims submission and payment are standardised with a J-code, thereby facilitating and clarifying billing and reimbursement from Medicare, Medicaid, and commercial insurance.
The Code, J9247, "Injection, melphalan flufenamide, 1mg" will go into effect on 1 October 2021.
